A Study of Zasocitinib for Psoriatic Arthritis
This study is testing a medicine called zasocitinib (TAK-279) for adults with active psoriatic arthritis (PsA), a condition that causes joint pain and skin problems. Researchers want to see how well zasocitinib works compared to a placebo (an inactive pill that looks like the study drug). You might be able to join if you are 18 or older, have been diagnosed with PsA for at least 3 months, and meet specific criteria. The main goal is to see if zasocitinib helps improve your PsA symptoms by Week 16. The study will last up to 60 weeks. The current status of this study is unclear, and it plans to enroll about 600 participants.
- Study design
- This is an interventional study where participants will receive either zasocitinib or a placebo. It plans to enroll 600 participants.
- What's involved
- Participants will receive either zasocitinib or a placebo. You will be in the study for up to 60 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured at Week 16, and participants will be in the study for up to 60 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
At a glance
Conditions
Where it's being run
123 sites across 82 statesStudy leadership
- Study Director · STUDY_DIRECTOR · Takeda
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 16 for Zasocitinib Dose A and B Compared to PlaceboAt Week 16
ACR responses are the numerical measurement of improvement in multiple disease assessment criteria. It is a composite clinical outcome assessment (COA) measure that includes both clinician-reported outcome assessments (ClinROs) and patient-reported outcomes (PROs). An ACR20 response is defined as: greater than or equal to (\>=) 20 percent (%) improvement from baseline in both swollen joint count 66 joints (SJC66) and tender joint count 68 joints (TJC68), and \>=20% improvement from baseline in 3 of the following 5 assessments: Patient's global assessment (PtGA) of psoriatic arthritis (PsA) pain; PtGA of PsA; physician's global assessment of disease activity (PGA) of PsA; participant's assessment of physical function as measured by health assessment questionnaire-disability index (HAQ-DI); high-sensitivity C-reactive protein (hsCRP). Percentage of participants achieving ACR20 response at Week 16 for zasocitinib Dose A and B compared to placebo will be reported.